Related Experiment Video

Updated: Jul 31, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

687

Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced

Ivona Mustapic1, Darija Bakovic2,3, Zora Susilovic-Grabovac2

  • 1Cardiovascular Diseases Department, University Hospital of Split, Soltanska 1, 21000, Split, Croatia. mateljanka@gmail.com.

Journal of Cardiovascular Translational Research
|May 8, 2023
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly improved left ventricular (LV) systolic function in heart failure with reduced ejection fraction (HFrEF) patients. Adding SGLT2i to optimized medical therapy enhanced myocardial work index and ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Limited understanding of sodium-glucose cotransporter 2 inhibitors (SGLT2i) effects on left ventricular (LV) systolic function in heart failure with reduced ejection fraction (HFrEF).
  • SGLT2i are increasingly used in HFrEF management, necessitating further investigation into their impact on cardiac mechanics.

Purpose of the Study:

  • To evaluate the effects of SGLT2 inhibitors on echocardiographic parameters of LV systolic function in HFrEF patients.
  • To compare changes in myocardial work index (MWI), 3D ejection fraction (3D LVEF), and global longitudinal strain (GLS) with and without SGLT2i treatment.

Main Methods:

  • Prospective study of 59 HFrEF outpatients divided into SGLT2i plus optimized medical therapy (OMT) group (n=41) and OMT alone group (n=18).
  • Echocardiographic parameters (MWI, 3D LVEF, GLS), NT-proBNP levels, and NYHA functional class were assessed at baseline and 3-month follow-up.

Main Results:

  • The SGLT2i+ group demonstrated significantly greater improvement in MWI compared to the SGLT2i- group at 3 months.
  • Both groups showed significant improvements in 3D LVEF, LV GLS, NT-proBNP, and NYHA class, with superior gains observed in the SGLT2i+ group.
  • SGLT2i addition to OMT led to enhanced LV systolic function and clinical status in HFrEF patients.

Conclusions:

  • Adding SGLT2 inhibitors to optimized medical therapy significantly improves LV systolic function in HFrEF outpatients.
  • SGLT2i therapy enhances myocardial work and overall cardiac performance beyond standard optimized medical therapy.
  • These findings support the role of SGLT2 inhibitors in improving cardiac mechanics and functional capacity in HFrEF.

Keywords:
3D-ejection fractionEchocardiographyGlobal longitudinal strainHeart failure with reduced ejection fractionMyocardial work efficiencyMyocardial work indexSGLT2 inhibitors

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K
Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

2.9K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
29
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
29